Electrical Vestibular Nerve Stimulation (VeNS) As a Treatment for Depression

Inclusion Criteria: * Signed Informed Consent * Male or female, age ≥ 18 years and ≤ 80 years at the time of signing informed consent * PHQ-9 score of \>/=10 at screening * On anti-depressant medication to treat depression (participant must only be on one Selective Serotonin or Norepinephrine Reuptake Inhibitor (SSRI/SNRI) for at least 1 year prior to baseline visit, and no longer than 5 years * Stable dose of anti-depressant (SSRI/SNRI) medication to treat depression, 3 months prior to baseline appointment * Stable medication regime for at least 4 weeks prior to the baseline visit * Can speak / read Hindi / English * Ability and willingness to complete all study visits and procedures; in particular an agreement to engage with trying to use the device per the study protocol * Ability and willingness to adhere to 30 minutes usage of the device at 5 days per week for the duration of the trial at clinic * Agree not to undergo any extreme lifestyle changes during the duration of the study that could impact sleep e.g. dietary or exercise changes Exclusion Criteria: * Patient Health Questionnaire-9 (PHQ-9) score of \<10 at screening * Risk of persistent self-harm or suicide * Diagnosis or history of bipolar disorder * History of a current psychotic disorder such as schizophrenia or other non-mood disorder psychosis * Diagnosis of substance use disorder or dependence * Use of recreational drugs (e.g nalgesics, depressants, stimulants, and hallucinogens). Subject can enrol after a washout period of 30 days * History of diagnosed cognitive impairment / disorder such as delirium or dementia * Previous diagnosis of a chronic viral infection, for example hepatitis or HIV. * History of stroke or head injury requiring intensive care or neurosurgery * Presence of permanently implanted battery-powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator, etc.) * History of epilepsy * History of severe tinnitus or vertigo * History of skin breakdown, eczema or other dermatological condition (e.g. psoriasis) affecting the skin behind the ears. * History or presence of malignancy within the last year (except basal and squamous cell skin cancer and in-situ carcinomas) * History of vestibular dysfunction or another inner ear disease * Regular use (more than twice a month) of antihistamine medication within the last 6 months * A diagnosis of myelofibrosis or myelodysplastic syndrome * Diagnosis of active migraines * Previous use of Modius device or any VeNS device * Participation in other clinical trials sponsored by Neurovalens * Any other medical condition, or medication use, that in the opinion of the PI is likely to make the subject refractory to VeNS. * Failure to use device daily during trial participation (no more than 14 consecutive days usage drop without reasonable explanation)